The role of high mobility group box-1 on the development of diabetes complications: A plausible pharmacological target
Diabetes and Vascular Disease Research · 2024
DOI: 10.1177/14791641241271949 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes and Vascular Disease Research, 2024. Verfasst von Nokwanda N Ngcobo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Pharmaceutical Sciences, School of Health Science, University of KwaZulu-Natal, Durban, South Africa. Hauptthemen laut MEDLINE: HMGB1 Protein, Signal Transduction, Receptor for Advanced Glycation End Products, Hypoglycemic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Mobilisation, Diabetes mellitus
Abstract (Originalsprache)
Background
Diabetes mellitus has emerged as a pressing global concern, with a notable increase in recent years. Despite advancements in treatment, existing medications struggle to halt the progression of diabetes and its associated complications. Increasing evidence underscores inflammation as a significant driver in the onset of diabetes mellitus. Therefore, perspectives on new therapies must consider shifting focus from metabolic stress to inflammation. High mobility group box (HMGB-1), a nuclear protein regulating gene expression, gained attention as an endogenous danger signal capable of sparking inflammatory responses upon release into the extracellular environment in the late 1990s.
Purpose
Given the parallels between inflammatory responses and type 2 diabetes (T2D) development, this review paper explores HMGB-1’s potential involvement in onset and progression of diabetes complications. Specifically, we will review and update the understanding of HMGB-1 and its inflammatory pathways in insulin resistance, diabetic nephropathy, diabetic neuropathy, and diabetic retinopathy.
Conclusions
HMGB-1 and its receptors i.e. receptor for advanced glycation end-products (RAGE) and toll-like receptors (TLRs) present promising targets for antidiabetic interventions. Ongoing and future projects in this realm hold promise for innovative approaches targeting HMGB-1-mediated inflammation to ameliorate diabetes and its complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discipline of Pharmaceutical Sciences, School of Health Science, University of KwaZulu-Natal, Durban, South Africa.
- Pharmacology Division, Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa.
ORCID-Profile: Nokwanda N Ngcobo
Zitieren
APA
Ngcobo, N. N., & Sibiya, N. H. (2024). The role of high mobility group box-1 on the development of diabetes complications: A plausible pharmacological target. Diabetes and Vascular Disease Research. https://doi.org/10.1177/14791641241271949
Vancouver
Ngcobo NN, Sibiya NH. The role of high mobility group box-1 on the development of diabetes complications: A plausible pharmacological target. Diabetes and Vascular Disease Research. 2024. doi:10.1177/14791641241271949
BibTeX
@article{Ngcobo2024,
author = {Ngcobo, Nokwanda N and Sibiya, Ntethelelo H},
title = {The role of high mobility group box-1 on the development of diabetes complications: A plausible pharmacological target},
journal = {Diabetes and Vascular Disease Research},
year = {2024},
doi = {10.1177/14791641241271949}
}
EUVIMED